Detalhe da pesquisa
1.
Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease.
Blood
; 132(9): 948-961, 2018 08 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-29967129
2.
The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib.
Blood
; 127(15): 1870-80, 2016 Apr 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-26773037
3.
Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.
Blood
; 127(6): 703-12, 2016 Feb 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-26603839
4.
BAM-matcher: a tool for rapid NGS sample matching.
Bioinformatics
; 32(17): 2699-701, 2016 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27153667
5.
Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline.
Blood
; 124(4): 511-8, 2014 Jul 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-24859364
6.
A comparative analysis of algorithms for somatic SNV detection in cancer.
Bioinformatics
; 29(18): 2223-30, 2013 Sep 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-23842810
7.
Poor response to second-line kinase inhibitors in chronic myeloid leukemia patients with multiple low-level mutations, irrespective of their resistance profile.
Blood
; 119(10): 2234-8, 2012 Mar 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-22210874
8.
Novel modes of MPL activation in triple-negative myeloproliferative neoplasms.
Pathology
; 55(1): 77-85, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36031433
9.
Many BCR-ABL1 compound mutations reported in chronic myeloid leukemia patients may actually be artifacts due to PCR-mediated recombination.
Blood
; 124(1): 153-5, 2014 Jul 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-24993880
10.
Targeted gene panels identify a high frequency of pathogenic germline variants in patients diagnosed with a hematological malignancy and at least one other independent cancer.
Leukemia
; 35(11): 3245-3256, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33850299
11.
The mutational burden of therapy-related myeloid neoplasms is similar to primary myelodysplastic syndrome but has a distinctive distribution.
Leukemia
; 33(12): 2842-2853, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31089247
12.
ASXL1 and BIM germ line variants predict response and identify CML patients with the greatest risk of imatinib failure.
Blood Adv
; 1(18): 1369-1381, 2017 Aug 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29296778
13.
Molecular methods in diagnosis and monitoring of haematological malignancies.
Pathology
; 43(6): 566-79, 2011 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-21881536
14.
Sensitive detection of BCR-ABL1 mutations in patients with chronic myeloid leukemia after imatinib resistance is predictive of outcome during subsequent therapy.
J Clin Oncol
; 29(32): 4250-9, 2011 Nov 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-21990409
15.
Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathways.
Leuk Lymphoma
; 52(11): 2139-47, 2011 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-21718141